Oyster Point Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Oyster Point Pharma's estimated annual revenue is currently $17.9M per year.
- Oyster Point Pharma's estimated revenue per employee is $94,921
- Oyster Point Pharma's total funding is $235.8M.
- Oyster Point Pharma's current valuation is $356.6M. (January 2022)
Employee Data
- Oyster Point Pharma has 189 Employees.
- Oyster Point Pharma grew their employee count by -21% last year.
Oyster Point Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Director Accounting | Reveal Email/Phone |
2 | Head CMC Drug Development | Reveal Email/Phone |
3 | SVP CMC and Operations | Reveal Email/Phone |
4 | SVP, Controller | Reveal Email/Phone |
5 | VP Regulatory Affairs | Reveal Email/Phone |
6 | VP, Market Access, Trade & Patient Services | Reveal Email/Phone |
7 | SVP and General Counsel | Reveal Email/Phone |
8 | Head Total Rewards | Reveal Email/Phone |
9 | Associate Director Finance | Reveal Email/Phone |
10 | Director Pharmaceutical Development | Reveal Email/Phone |
Oyster Point Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Oyster Point Pharma?
Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The companyￃﾢ￢ﾂﾬ￢ﾄﾢs initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board. For more information visit oysterpointrx.com and follow on Twitter at @OysterPointRx.
keywords:N/A
$235.8M
Total Funding
189
Number of Employees
$17.9M
Revenue (est)
-21%
Employee Growth %
$356.6M
Valuation
N/A
Accelerator
Oyster Point Pharma News
Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-...
Last year, under Romanelli, JiXing struck a licensing deal with Oyster Point Pharma for two nasal sprays that could provide treatment...
Oyster Point Pharma, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of...
Oyster Point Pharma, Inc., a Princeton, NJ-based clinical-stage pharmaceutical company with an initial focus on developing novel therapies to treat Dry Eye Disease, raised $93m in Series B financing. The round was co-led by Invus Opportunities and Flying L Partners in collaboration with Falcon ...
Oyster Point Pharmaceuticals Inc., a San Francisco, CA-based developer of novel therapies for dry eye and other diseases of the ocular surface, completed a $22m Series A financing. The round was led by New Enterprise Associates and Versant Ventures. The company intends to use the proceeds for ...
Other Companies in Princeton
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $37.4M | 189 | 2% | N/A |
#2 | $67.2M | 189 | 25% | N/A |
#3 | $56.7M | 191 | 7% | N/A |
#4 | $30.5M | 191 | -6% | N/A |
#5 | $69M | 193 | 39% | N/A |